MAPK8 and neoplasm: Furthermore, the combined use of Nrf2 inhibitors targeting Nrf2 signaling and ERK inhibitors plus p38 activators or JNK activators targeting MAPK signaling pathways, or drugs targeting mitochondria dysfunction pathway might produce better anti-tumor effects on PAs.